In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

"ATLAS ACS 2-TIMI 51: Rivaroxaban in Patients with ST-Elevation Myocardial Infarction: Results from ATLAS ACS 2-TIMI 51: "

ACCA



 

Presenter: Jessica Mega | see Discussant report

 

Abstract:

 

Background
Patients remain at risk of recurrent cardiovascular events despite medical therapies and interventional strategies following a ST-segment elevation myocardial infarction (STEMI).  In the ATLAS ACS 2-TIMI 51 trial, the factor Xa inhibitor rivaroxaban reduced cardiovascular events in ACS patients.  The present analysis reports the results of rivaroxaban versus placebo in the pre-specified subgroup of patients following a STEMI.

Methods
ATLAS ACS 2-TIMI 51 was a randomized, placebo-controlled study involving 44 countries and 15,526 patients.  The present analysis includes 7,817 patients following a STEMI who underwent randomization to twice daily dosing of either rivaroxaban 2.5 mg, rivaroxaban 5 mg, or placebo.  Data are presented as 2 year Kaplan–Meier event rates, and testing was based on the log-rank test, stratified by the intention to use a thienopyridine.

Results
Rivaroxaban was associated with a reduction in the composite primary efficacy endpoint of cardiovascular death, myocardial infarction, or stroke, as compared with placebo (8.4% vs. 10.6%, HR 0.81, 95% CI 0.67-0.97, P=0.019).  Rivaroxaban 2.5 mg twice daily (8.7% vs. 10.6%, P=0.047) and 5 mg twice daily (8.2% vs. 10.6%, P=0.051) as compared with placebo exhibited directionally consistent reductions in the primary efficacy endpoint.  Rivaroxaban 2.5 mg twice daily reduced cardiovascular death (2.5% vs. 4.2%, P=0.006) and all-cause death (3.0% vs. 4.7%, P=0.008); this survival benefit was not seen with 5 mg twice daily dose.  Rivaroxaban, as compared with placebo, increased the rates of TIMI major bleeding not related to CABG (2.2% vs. 0.6%, P<0.001) and intracranial hemorrhage (0.6% vs. 0.1%, P=0.015), without a significant increase in fatal bleeding (0.2% vs. 0.1%, P=0.51).  Rivaroxaban 2.5 mg twice daily resulted in less fatal bleeding than rivaroxaban 5 mg twice daily (1 event vs. 8 events, P=0.018).

Summary
In patients with a recent STEMI, rivaroxaban reduced the risk of the composite endpoint of cardiovascular death, myocardial infarction, or stroke, and the 2.5 mg twice daily dose demonstrated a mortality benefit.  Rivaroxaban as compared with placebo increased the risk of major bleeding and intracranial hemorrhage, but there was no increase in fatal bleeding.

Conclusions
Treatment with very low dose rivaroxaban (2.5 mg BID) offers an effective strategy to reduce thrombotic events in patients following a STEMI.


Discussant: Andreas Michael | see Presenter abstract 

 

 

References


710007 - 710008

SessionTitle:

Clinical Trial & Registry Update II: Updates on Heart Failure and Coronary Artery Disease

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.